Imago BioSciences to Participate in Upcoming Investor Conferences

Sept. 8, 2020 12:00 UTC

 

 
 

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Imago Biosciences, Inc. (“Imago”), a private clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that Hugh Young Rienhoff, Jr. M.D., chief executive officer, will present a corporate overview at two upcoming investor conferences.

  • Citi’s 15th Annual BioPharma Virtual Conference
    Date: Tuesday, September 8th 2020
    Time: 2:20 p.m. ET
    Logistics: If you’d like to register and attend the company presentation, click here to learn more.
  • H.C. Wainwright 22nd Annual Global Investment Virtual Conference
    Date:
    Monday, September 14th 2020
    Time: 10:00 a.m. ET
    Logistics: If you’d like to register and attend the company presentation, click here to learn more.

About Imago BioSciences

Imago BioSciences is a private clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics targeting epigenetic enzymes. Imago has developed a series of compounds that alter the activity and function of LSD1, an epigenetic enzyme critical for cancer stem cell function and blood cell maturation and function. Imago is advancing the clinical development of its first LSD1 inhibitor, IMG-7289 (bomedemstat), for the treatment of myeloid neoplasms including myelofibrosis, essential thrombocythemia and polycythemia vera. Imago BioSciences is backed by leading strategic and venture investors including a fund managed by Blackstone Life Sciences, Frazier Healthcare Partners, Omega Funds, Amgen Ventures, MRL Ventures Fund, HighLight Capital, Pharmaron, Greenspring Associates and Xeraya Capital. The company is based in South San Francisco, California. To learn more, visit www.imagobio.com, www.myelofibrosisclinicalstudy.com and follow us on Twitter @ImagoBioRx, Facebook and LinkedIn.  

Contacts

Steve Kunszabo 
Canale Communications 
steve@canalecomm.com 
(619) 849-5388 

 
 

Source: Imago BioSciences

Back to news